A Randomized, Placebo-Controlled Multi-Site Phase 2 Study Evaluation the Safety and Efficacy of Preemptive Treatment With CMX001 for the Prevention of Adenovirus Disease Following Hematopoietic Stem Cell Transplantation in Adults and Children.

Trial Profile

A Randomized, Placebo-Controlled Multi-Site Phase 2 Study Evaluation the Safety and Efficacy of Preemptive Treatment With CMX001 for the Prevention of Adenovirus Disease Following Hematopoietic Stem Cell Transplantation in Adults and Children.

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Sep 2014

At a glance

  • Drugs Brincidofovir (Primary)
  • Indications Adenovirus infections
  • Focus Proof of concept; Therapeutic Use
  • Acronyms Adv-Halt
  • Sponsors Chimerix
  • Most Recent Events

    • 09 Sep 2014 Results presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy.
    • 08 Sep 2014 Results published in the Media Release.
    • 04 Nov 2013 Results presented at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top